NCT01127893View on ClinicalTrials.gov

Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis

PHASE3TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

June 15, 2010

Primary Completion Date

September 29, 2010

Study Completion Date

September 29, 2010

Conditions
Osteoarthritis
Interventions
BIOLOGICAL

Tanezumab

Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections

BIOLOGICAL

Tanezumab

Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections

BIOLOGICAL

Tanezumab

Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections

Trial Locations (1)

91942

Triwest Research Associates, La Mesa

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY